[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100353276":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":60,"centralContacts":53,"locations":53,"responsibleParty":65,"collaborators":53,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":53,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":53,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":53,"overallStatus":87,"whyStopped":53,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":53},{"fullName":5,"class":6},"Organon and Co","INDUSTRY",[8,16,20,24,30],{"label":9,"type":10,"description":11,"interventionNames":12},"MFNS 25 mcg QD","EXPERIMENTAL","Mometasone furoate nasal spray 12.5 mcg\u002Fspray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg\u002F5 mL was to be used for relief of intolerable SAR symptoms.",[13,14,15],"Drug: Mometasone furoate nasal spray","Drug: Placebo nasal spray","Drug: Chlorpheniramine maleate syrup",{"label":17,"type":10,"description":18,"interventionNames":19},"MFNS 100 mcg QD","Mometasone furoate nasal spray 50 mcg\u002Fspray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg\u002F5 mL was to be used for relief of intolerable SAR symptoms.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"MFNS 200 mcg QD","Mometasone furoate nasal spray 100 mcg\u002Fspray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg\u002F5 mL was to be used for relief of intolerable SAR symptoms.",[13,14,15],{"label":25,"type":26,"description":27,"interventionNames":28},"BDP 84 mcg BID","ACTIVE_COMPARATOR","Beclomethasone dipropionate nasal spray 42 mcg\u002Fspray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg\u002F5 mL was to be used for relief of intolerable SAR symptoms.",[29,15],"Drug: Beclomethasone dipropionate nasal spray",{"label":31,"type":32,"description":33,"interventionNames":34},"Placebo","PLACEBO_COMPARATOR","Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg\u002F5 mL was to be used for relief of intolerable SAR symptoms.",[14,15],[36,45,50,54],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","Mometasone furoate nasal spray","intranasal administration",[17,21,9],[42,43,44],"Nasonex®","MK-0887","SCH 032088",{"type":37,"name":46,"description":39,"armGroupLabels":47,"otherNames":48},"Beclomethasone dipropionate nasal spray",[25],[49],"Vancenase®",{"type":37,"name":51,"description":39,"armGroupLabels":52,"otherNames":53},"Placebo nasal spray",[17,21,9,31],null,{"type":37,"name":55,"description":56,"armGroupLabels":57,"otherNames":58},"Chlorpheniramine maleate syrup","oral administration",[25,17,21,9,31],[59],"ChlorTrimeton Syrup",[61],{"name":62,"affiliation":63,"role":64},"Medical Director","Merck Sharp & Dohme LLC","STUDY_DIRECTOR",{"type":66,"investigatorFullName":53,"investigatorTitle":53,"investigatorAffiliation":53,"oldNameTitle":53,"oldOrganization":53},"SPONSOR","100353276","phase-3-dose-ranging-study-of-mometasone-furoate-mk-0887sch-032088-nasal-spray-in-the-treatment-of-children-ages-6-11-with-seasonal-allergic-rhinitis-c95-161-100353276",true,"NCT03879772","Dose-Ranging Study of Mometasone Furoate (MK-0887\u002FSCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)","Dose-Ranging Study of Mometasone Furoate Nasal Spray (SCH 32088) in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (Protocol C95-161)","Inclusion Criteria:\n\n* Have at least a one-year history of seasonal allergic rhinitis which previously required treatment for tree and\u002For grass pollen\n* Have a positive skin test response to an appropriate tree and\u002For grass seasonal allergen within the last year.\n* Must be free of any clinically significant disease other than seasonal allergic rhinitis.\n* Must be pre-menarcheal.\n\nExclusion Criteria:\n\n* History of asthma which requires chronic use of inhaled or systemic corticosteroids.\n* Current or history of frequent, clinically significant sinusitis or chronic purulent postnasal drip.\n* History of rhinitis medicamentosa.\n* History of clinically significant nasal candidiasis.\n* History of multiple drug allergies or allergy\u002Fintolerance to corticosteroids or antihistamines.\n* History of upper respiratory tract or sinus infection that required antibiotic therapy within the previous 2 weeks, or viral upper respiratory infection within 7 days prior to Screening.\n* History of nasal structural abnormalities, including large nasal polyps and marked septal deviation, that significantly interfere with nasal air flow.\n* History of dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines.\n* History of investigational drug use in the last 30 days.\n* History of immunotherapy (desensitizing therapy), unless on a stable maintenance schedule for at least one month prior to Screening.",false,"ALL","6 Years","11 Years",{"count":79,"type":80},679,"ACTUAL","INTERVENTIONAL",[83],"PHASE3","The purpose of this study was to identify the lowest dosage of mometasone furoate nasal spray (MFNS) that provided adequate efficacy with an acceptable safety profile for children (ages 6-11) with seasonal allergic rhinitis (SAR). The MFNS dose levels of 25, 100, and 200 mcg QD were compared with beclomethasone dipropionate (BDP), as an active control, and placebo.",[86],"Rhinitis, Allergic, Seasonal","COMPLETED","2022-02-07",{"date":90,"type":80},"2022-02-09",{"date":92,"type":80},"1996-03-12",{"date":94,"type":80},"1996-07-01",{"name":5,"class":6}]